• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dianthus Therapeutics Inc.

    3/9/26 9:04:29 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNTH alert in real time by email
    S-8 1 dnth-20260309.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 9, 2026

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

     

     

     

     

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

     

     

     

     

     

     

     

    Dianthus Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

     

    Delaware

     

    81-0724163

     

     

    (State or Other Jurisdiction of

    Incorporation or Organization

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

     

     

     

     

     

     

     

    7 Times Square, 43rd Floor

    New York, NY 10036

     

     

    (Address of Principal Executive Offices, Zip Code)

     

     

     

     

     

     

     

     

     

     

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan

    Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended

     Dianthus Therapeutics, Inc. Equity Inducement Plan

     

     

     

    (Full title of the plan)

     

     

     

     

     

     

     

     

     

     

     

     

    Adam M. Veness, Esq.

    Senior Vice President, General Counsel and Secretary

    Dianthus Therapeutics, Inc.

    7 Times Square, 43rd Floor

    New York, NY 10036

    (929) 999-4055

     

     

     

     

     

     

     

    Copies to:

     

     

    Ryan A. Murr, Esq.

    Branden C. Berns, Esq.

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

    Telephone: (415) 393-8200

    Facsimile: (415) 393-8306

     

     

     

     

     

     

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) registers (i) 2,161,025 additional shares of common stock, $0.001 par value per share (“Common Stock”), of Dianthus Therapeutics, Inc. (the “Registrant”) under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “Incentive Plan”), (ii) 62,500 additional shares of Common Stock under the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (the “ESPP”), and (iii) 600,000 additional shares under the Dianthus Therapeutics, Inc. Equity Inducement Plan (the "Inducement Plan"), which was approved by the Registrant’s board of directors on December 17, 2025 to provide for the grant of additional inducement awards under the Inducement Plan in accordance with the requirement of Nasdaq Listing Rule 5635(c)(4).

    The number of shares of Common Stock reserved and available for issuance under the Incentive Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator (as defined in the Incentive Plan). Accordingly, on January 1, 2026, the number of shares of Common Stock reserved and available for issuance under the Incentive Plan increased by 2,161,025 shares. The additional shares are of the same class as other securities relating to the Incentive Plan for which the Registrant’s registration statement filed Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2025, August 8, 2024, March 21, 2024, October 4, 2023, March 8, 2022, March 3, 2021, March 3, 2020, March 19, 2019 and June 22, 2018 (Registration Nos. 333-285709, 333-281381, 333-278151, 333-274865, 333-263358, 333-253815, 333-236853, 333-230387, and 333-225838), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Incentive Plan are in addition to the shares of Common Stock registered on such registration statements.

    The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1 by an amount equal to the least of (i) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the ESPP). Accordingly, on January 1, 2026, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 62,500. The additional shares are of the same class as other securities relating to the ESPP for which the Registrant’s registration statement filed on Form S-8 filed with the SEC on March 11, 2025, March 21, 2024, March 8, 2022 and August 8, 2019 (Registration Nos. 333-285709, 333-278151, 333-263358 and 333-233125), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the ESPP are in addition to the shares of Common Stock registered on such registration statements.

     

    The number of shares of Common Stock reserved and available for issuance under the Inducement Plan was increased by an additional 600,000 shares pursuant to approval by the Registrant's Board of Directors on December 17, 2025. The additional shares are of the same class as other securities relating to the Inducement Plan for which the Registrant’s registration statement filed on Form S-8 filed with the SEC on March 21, 2024 (Registration No. 333-278151), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Inducement Plan are in addition to the shares of Common Stock registered on such registration statements.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     


     

    Exhibit

    Number

     

    Description

    4.1

     

    Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 12, 2023)

    4.2

     

    Third Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 21, 2024)

    5.1*

     

    Opinion of Gibson, Dunn & Crutcher LLP

    23.1*

     

    Consent of Deloitte & Touche LLP, independent registered public accounting firm

    23.2*

     

    Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)

    24.1*

     

    Power of Attorney (included on the signature page to this Registration Statement)

    99.1

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 28, 2024)

    99.2

     

    Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024)

    99.3

     

    Dianthus Therapeutics, Inc. Equity Inducement Plan (Amended and Restated on December 17, 2025)

    107.1*

     

    Filing Fee Table

     

    * Filed herewith.

     


     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 9, 2026.

     

     

    DIANTHUS THERAPEUTICS, INC.

     

     

     

    By:

    /s/ Ryan Savitz

     

    Name:

    Ryan Savitz

     

    Title:

    Executive Vice President, Chief Financial Officer and Chief Business Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Marino Garcia, Ryan Savitz and Adam Veness and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

     

    Signature

     

    Title

    Date

     

     

     

     

    /s/ Marino Garcia

     

    President, Chief Executive Officer and Director

    March 9, 2026

    Marino Garcia

     

    (Principal Executive Officer)

     

     

     

     

     

    /s/ Ryan Savitz

     

    Executive Vice President, Chief Financial Officer and Chief Business Officer

    March 9, 2026

    Ryan Savitz

     

    (Principal Financial Officer)

     

     

     

     

     

    /s/ Edward Carr

     

    Chief Accounting Officer

    March 9, 2026

    Edward Carr

     

    (Principal Accounting Officer)

     

     

     

     

     

    /s/ Alison Lawton

     

    Director and Chair of the Board

    March 9, 2026

    Alison Lawton

     

     

     

     

     

     

     

    /s/ Sujay Kango

     

    Director

    March 9, 2026

    Sujay Kango

     

     

     

     

     

     

     

    /s/ Anne McGeorge

     

    Director

    March 9, 2026

    Anne McGeorge

     

     

     

     

     

     

     

    /s/ Steve Romano, M.D.

     

    Director

    March 9, 2026

    Steven Romano, M.D.

     

     

     

     

     

     

     

    /s/ Simon Read, Ph.D.

     

    Director

    March 9, 2026

    Simon Read, Ph.D.

     

     

     

     

     

     

     

    /s/ Paula Soteropoulos

     

    Director

    March 9, 2026

    Paula Soteropoulos

     

     

     

     

     

     

     

    /s/ Jonathan Violin, Ph.D.

     

    Director

    March 9, 2026

    Jonathan Violin, Ph.D.

     

     

     

     


    Get the next $DNTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNTH

    DatePrice TargetRatingAnalyst
    10/14/2025$56.00Buy
    Truist
    7/2/2025Outperform
    William Blair
    12/20/2024Buy
    TD Cowen
    10/3/2024$48.00Outperform
    Oppenheimer
    7/26/2024$58.00Outperform
    Robert W. Baird
    6/27/2024Overweight
    Cantor Fitzgerald
    5/16/2024$40.00Buy
    H.C. Wainwright
    2/15/2024$44.00Buy
    Stifel
    More analyst ratings

    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Carr Edward

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:42:10 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, General Counsel and Sec. Veness Adam M

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:41:33 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Head of R&D Randhawa Simrat

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:40:55 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

    NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, l

    3/9/26 4:01:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

    Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into

    3/9/26 7:09:07 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.

    3/9/26 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    SEC Filings

    View All

    SEC Form 424B5 filed by Dianthus Therapeutics Inc.

    424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    3/9/26 5:25:52 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Dianthus Therapeutics Inc.

    S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    3/9/26 9:04:29 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Dianthus Therapeutics Inc.

    10-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    3/9/26 7:21:41 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Dianthus Therapeutics with a new price target

    Truist initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $56.00

    10/14/25 8:48:52 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Dianthus Therapeutics

    William Blair initiated coverage of Dianthus Therapeutics with a rating of Outperform

    7/2/25 8:17:26 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Dianthus Therapeutics

    TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

    12/20/24 7:31:45 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Financials

    Live finance-specific insights

    View All

    Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

    Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for 2H'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26; update on indication prioritization planned for 1H'26 $514.4 million of cash as of December 31, 2025 provides runway into

    3/9/26 7:09:07 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C. Q2W dose arm from Part B, and expects to enroll up to 256 patients in Part A to randomize 128 patients in Part B Independent DSMB review confirmed GO decision; no related serious infections, no clinical symptoms of autoimmune activation, and no related serious adverse events or discontinuations GO decision supports continued development of claseprubart 300mg/2mL Q2W S.C.

    3/9/26 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and ans

    3/8/26 5:00:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Leadership Updates

    Live Leadership Updates

    View All

    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

    Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

    5/22/25 4:10:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

    Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

    3/5/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

    Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

    11/29/23 4:05:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

    SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    12/3/24 9:19:18 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dianthus Therapeutics Inc.

    SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/22/24 4:41:50 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

    SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/14/24 5:48:32 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care